Gaudet D, Vohl M C, Julien P, Tremblay G, Perron P, Gagné C, Bergeron J, Moorjani S, Després J P
Chicoutimi Hospital Lipid Clinic, Quebec, Canada.
Am J Cardiol. 1998 Aug 1;82(3):299-305. doi: 10.1016/s0002-9149(98)00328-2.
Men with low-density lipoprotein receptor gene mutations causing familial hypercholesterolemia (FH) are at high risk of premature coronary artery disease (CAD). The dyslipidemic state found among patients who are heterozygous for mutations in the lipoprotein lipase (LPL) gene may also increase the risk of CAD. In the present study, the association of the heterozygous forms of low-density lipoprotein receptor gene mutations causing FH as well as of LPL gene mutations causing (P207L and G188E) or not causing (D9N and N291S) complete loss of LPL activity with angiographically assessed CAD was estimated in a cohort of 412 French Canadian men aged <60 years who consecutively underwent coronary angiography for the investigation of retrosternal pain. The frequency of FH as well as of LPL gene mutations tended to increase with the number of narrowed coronary arteries. However, CAD occurred earlier in FH patients than in partly LPL-deficient patients. Indeed, the proportion of men affected by FH was of 16.4% in those <45 years of age, and solely 4.3% among those between 56 and 60 years of age (p <0.0001). In contrast, the LPL gene defect was found in only 4.0% of men aged <45 years, whereas this prevalence reached 8.3% among those aged 56 to 60 years. In multivariate analyses, the association of LPL with CAD was not independent of age, high-density lipoprotein cholesterol concentrations, and other covariates included at baseline, and was not affected by the type of mutation in the LPL gene. In contrast, FH was associated with CAD with minimal contribution of other cardiovascular risk factors. However, the relation between FH and CAD was at least partly dependent on plasma apolipoprotein B concentrations. In the different regression models, fasting insulin and plasma high-density lipoprotein cholesterol concentrations were important covariates of CAD, whether or not patients were affected by FH or LPL deficiency. In conclusion, the association of LPL gene mutations with CAD was delayed compared with FH, appeared to be markedly exacerbated by the presence of additional risk factors, and was not affected by the type of mutation in the LPL gene.
携带导致家族性高胆固醇血症(FH)的低密度脂蛋白受体基因突变的男性患早发性冠状动脉疾病(CAD)的风险很高。脂蛋白脂肪酶(LPL)基因突变的杂合子患者中发现的血脂异常状态也可能增加CAD的风险。在本研究中,在一组412名年龄小于60岁的法裔加拿大男性队列中,评估了导致FH的低密度脂蛋白受体基因突变的杂合形式以及导致(P207L和G188E)或不导致(D9N和N291S)LPL活性完全丧失的LPL基因突变与血管造影评估的CAD之间的关联,这些男性因胸骨后疼痛连续接受冠状动脉造影检查。FH以及LPL基因突变的频率往往随着冠状动脉狭窄数量的增加而增加。然而,CAD在FH患者中比在部分LPL缺乏的患者中出现得更早。事实上,年龄小于45岁的男性中受FH影响的比例为16.4%,而在56至60岁的男性中仅为4.3%(p<0.0001)。相比之下,LPL基因缺陷仅在45岁以下男性中发现4.0%,而在56至60岁男性中的患病率达到8.3%。在多变量分析中,LPL与CAD的关联并不独立于年龄、高密度脂蛋白胆固醇浓度以及基线时纳入的其他协变量,并且不受LPL基因突变类型的影响。相比之下,FH与CAD相关,其他心血管危险因素的贡献最小。然而,FH与CAD之间的关系至少部分取决于血浆载脂蛋白B浓度。在不同的回归模型中,无论患者是否受FH或LPL缺乏影响,空腹胰岛素和血浆高密度脂蛋白胆固醇浓度都是CAD的重要协变量。总之,与FH相比,LPL基因突变与CAD的关联出现较晚,似乎因其他危险因素的存在而明显加剧,并且不受LPL基因突变类型的影响。